Isavuconazole use and TDM in real-world pediatric practice.

Autor: Fernández Ledesma B; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil. Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Mendoza-Palomar N; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil. Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Melendo Pérez S; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil. Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Fernández-Polo A; Pharmacy Department, Hospital Infantil, Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Renedo Miró B; Pharmacy Department, Hospital Infantil, Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Pau Parra A; Pharmacy Department, Hospital Infantil, Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Luque Pardos S; Pharmacy Department, Hospital del Mar, Barcelona, Catalonia, Spain., Grau Cerrato S; Pharmacy Department, Hospital del Mar, Barcelona, Catalonia, Spain., Vima Bofarull J; Department of Clinical Biochemistry, Central Clinical Laboratories, Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Martín-Gómez MT; Microbiology Department, Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain., Pujol Jover M; Pediatric Intensive Care Unit, Hospital Infantil, Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Benítez-Carbante MI; Pediatric Oncology and Hematology Department, Hospital Infantil. Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Díaz de Heredia C; Pediatric Oncology and Hematology Department, Hospital Infantil. Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Barcelona, Catalonia, Spain., Soler-Palacin P; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Infantil. Vall d'Hebron Barcelona Hospital Campus, Institut de Recerca Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Jazyk: angličtina
Zdroj: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Dec 14; Vol. 67 (12), pp. e0082923. Date of Electronic Publication: 2023 Nov 14.
DOI: 10.1128/aac.00829-23
Abstrakt: Isavuconazole (ISA) is approved for treating invasive aspergillosis and mucormycosis in adults, but its use in children remains off-label. We report on the use of ISA in real-world pediatric practice with 15 patients receiving ISA for treatment of invasive fungal infections. Therapeutic drug monitoring (TDM) was performed in all patients, with 52/111 (46.8%) C trough determinations out of range, thus supporting the need for TDM in children, especially those receiving extracorporeal membrane oxygenation (ECMO).
Competing Interests: The authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz: